Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1022477

Above What Age Should Ibrutinib Not Be Given With R-CHOP to Patients With Non-GBC DLBCL?


Skelin, Marko; Lucijanić, Marko; Miketic, Tanja
Above What Age Should Ibrutinib Not Be Given With R-CHOP to Patients With Non-GBC DLBCL? // Journal of Clinical Oncology, [Epub ahead of print] (2019), [Epub ahead of print]-[Epub ahead of print] doi:10.1200/jco.19.01048 (međunarodna recenzija, pismo uredniku, znanstveni)


CROSBI ID: 1022477 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Above What Age Should Ibrutinib Not Be Given With R-CHOP to Patients With Non-GBC DLBCL?

Autori
Skelin, Marko ; Lucijanić, Marko ; Miketic, Tanja

Izvornik
Journal of Clinical Oncology (0732-183X) [Epub ahead of print] (2019); [Epub ahead of print]-[Epub ahead of print]

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pismo uredniku, znanstveni

Ključne riječi
ibrutinib ; non-GBC DLBCL

Sažetak
Results of the PHOENIX trial suggested significant interactions between age, treatment arm, and outcomes in non-GBC DLBCL patients treated with ibrutinib. In this letter to the editor we have addressed potential flaws of PHOENIX trial analysis and highlighted potential safety concerns of ibrutinib use in this specific population.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove:
Opća bolnica Šibenik

Profili:

Avatar Url Marko Skelin (autor)

Avatar Url Marko Lucijanić (autor)

Citiraj ovu publikaciju

Skelin, Marko; Lucijanić, Marko; Miketic, Tanja
Above What Age Should Ibrutinib Not Be Given With R-CHOP to Patients With Non-GBC DLBCL? // Journal of Clinical Oncology, [Epub ahead of print] (2019), [Epub ahead of print]-[Epub ahead of print] doi:10.1200/jco.19.01048 (međunarodna recenzija, pismo uredniku, znanstveni)
Skelin, M., Lucijanić, M. & Miketic, T. (2019) Above What Age Should Ibrutinib Not Be Given With R-CHOP to Patients With Non-GBC DLBCL?. Journal of Clinical Oncology, [Epub ahead of print], [Epub ahead of print]-[Epub ahead of print] doi:10.1200/jco.19.01048.
@article{article, year = {2019}, pages = {[Epub ahead of print]-[Epub ahead of print]}, DOI = {10.1200/jco.19.01048}, keywords = {ibrutinib, non-GBC DLBCL}, journal = {Journal of Clinical Oncology}, doi = {10.1200/jco.19.01048}, volume = {[Epub ahead of print]}, issn = {0732-183X}, title = {Above What Age Should Ibrutinib Not Be Given With R-CHOP to Patients With Non-GBC DLBCL?}, keyword = {ibrutinib, non-GBC DLBCL} }
@article{article, year = {2019}, pages = {[Epub ahead of print]-[Epub ahead of print]}, DOI = {10.1200/jco.19.01048}, keywords = {ibrutinib, non-GBC DLBCL}, journal = {Journal of Clinical Oncology}, doi = {10.1200/jco.19.01048}, volume = {[Epub ahead of print]}, issn = {0732-183X}, title = {Above What Age Should Ibrutinib Not Be Given With R-CHOP to Patients With Non-GBC DLBCL?}, keyword = {ibrutinib, non-GBC DLBCL} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
  • Scopus
  • MEDLINE


Citati





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font